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April 2010820 OhkiDr Carlos Timaran (Dallas, Tex). This is an excellent study.
I think this is the future and we are going to have to adopt this type
of technology. I have two questions. First, catheterization of the
visceral renal vessels is just one part of the fenestrated EVAR
procedure. Equally important is to be able to advance the stiff
guidewires and guiding catheters or sheaths or the stents or the
stent grafts themselves. Does your system assist you to advance
the stiff guidewires or the guiding sheaths? You can catheterize the
vessel, but you may not get your stent or guidewire to advance.
The second issue is when you have a type II thoracoabdominal
aortic aneurysm, you are talking about branched EVAR. What you
showed us today looked more like an infrarenal AAA. Can you
comment on that?
Dr Riga. With regards to your first question, the CE marked
catheter that we are testing at the moment is a venous ablation
catheter; the outer sheath is 14 French in diameter and the inner
guide is 12 French in diameter. It is quite versatile in that you can
pass stiff wires and side-branch stents through its lumen. It is,
however, quite large to confidently cannulate a diseased, say, renal
artery in a clinical setting, so I think Hansen will need to work on
catheter development and produce smaller diameter catheters
based on the existing platform. There is always a risk that a smaller
diameter catheter may compromise the current stability of the
standard device but we will have to assess this with further in vitro
physician includes near or complete elimination of both radiationand in vivo studies. With regards to your second question, for the
purpose of this study, we used the visceral segment of a Type II
TAAA model. There is a larger aneurysmal dilatation of the infra-
renal portion. We placed the stent in fixed suspension to simulate
the partial deployment of the Cook platform in fenestrated stent
grafting. Essentially, we wanted to assess whether the operator can
get from A to B, through the fenestration, while bridging the gap
between the stent and the target vessel through a tortuous iliac
anatomy.
Dr Vikram Kashyap (Cleveland, Ohio). I congratulate you on
a beautiful study. The focus on your talk was on imaging. But when
talking about catheterization, the other part of it is the tactile
feedback. My question, is there a torque or a force limit on this
robotic system so you don’t overwhelm the arterial integrity at the
curves of these aortic junctures?
Dr Riga. Robotic systems have been criticized in the past for
the lack of feedback that the operator can get from manual cannu-
lation techniques. This particular system has a force sensor at the
tip, which gives you a visual presentation of the amount of force
that is applied against the tissue. There is a degree of tactile
feedback as well. But again, this has never been used in the arterial
system before, so to be able to accurately and confidently assess it,
we need to perform clinical studies in man.INVITED COMMENTARYTakao Ohki, MD, Tokyo, Japan
Despite the obvious benefit of a fenestrated/branched stent
graft (FSG) that enables minimally invasive therapy for thoracoab-
dominal aneurysm, its use has been limited for several reasons,
including absence of reimbursement and the technical difficulties.
The latter is apparent from our experience at Jikei University.
During the last 3 years, we have performed 610 endovascular
aneurysm repairs (EVAR) and 45 FSG procedures. The mean
operating time was two times longer for FSG, but the most notable
difference existed in the fluoroscopic time, which was 29 minutes
for EVAR and 130 minutes for FSG. We spent most of the
fluoroscopic time on cannulating the visceral arteries.
Riga and colleagues have shown a significant benefit of the
robotic endovascular catheter for FSG, at least in a bench model.
The robotic system was able to reduce the fluoroscopic time of
cannulating all four vessels by an impressive 83% and the number of
wire and catheter movements by 92%. Although not evaluated in
this study, the additional benefit of the robotic system for theexposure and physical stress secondary to standing (often in a
awkward posture) long hours wearing heavy lead aprons.
One limitation of this study is that only catheterization of the
visceral arteries was assessed, whereas in a real-world setting,
advancement and accurate deployment of side branch stents are
involved. In addition, due to the large crossing profile of the
current robotic catheter, it is not possible to intubate multiple
visceral arteries simultaneously with a guiding sheath.
As the authors pointed out in the Discussion, the cost of
installing the robotic system may become an issue. However,
because the well-being of both the patient (potential reduction in
complication rate) and the physician is priceless, if this robotic
system proves to be as beneficial in a clinical setting as it was in this
bench model, cost should not be an issue. I personally cannot wait
to use the robotic system, because my neck and back will not
tolerate too many more complex endovascular procedures, includ-
ing FSG procedures.
